Article

Virtual Screening and Identification of Non-covalent Reversible Small-molecule BTK Inhibitors from a Library of Known Bioactive Compounds

2026-06-18

Abstract excerpt

<title>Abstract</title> <p>Bruton’s tyrosine kinase (BTK) is a key mediator of B-cell receptor signaling and an established therapeutic target for chronic lymphocytic leukemia. Despite the clinical success of covalent BTK inhibitors, acquired resistance associated with Cys481 mutations has created an urgent need for alternative reversible inhibition strategies. In this study, a structure-based virtual screening w...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8c042827-7315-510f-bcba-151aee8b898b
DOI: 10.21203/rs.3.rs-9926721/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Virtual Screening and Identification of Non-covalent Reversible Small-molecule BTK Inhibitors from a Library of Known Bioactive CompoundsDOI 10.21203/rs.3.rs-9926721/v1Read

Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.Semantic proximity Read

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future DirectionsSemantic proximity Read

More than an attachment module: covalent inhibitor warheads influence BTK dynamics and functionSemantic proximity Read

Computational insights into mutation-induced binding changes in Bruton's Tyrosine Kinase with non-covalent inhibitors.Semantic proximity Read

From covalent to reversible: the expanding role of BTK inhibitors in chronic lymphocytic leukemia.Semantic proximity Read

Screening and Characterization of Allosteric Small Molecules Targeting Bruton's Tyrosine Kinase.Semantic proximity Read

Battling BTK mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations in Waldenström macroglobulinemia therapy: structural mechanistic insights on the role of fenebrutinib.Semantic proximity Read

Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted TherapySemantic proximity Read

Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemiaSemantic proximity Read

Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.Semantic proximity Read

Targeting Bruton's Tyrosine Kinase in CLL.Semantic proximity Read

Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).Semantic proximity Read